FDA Approves Subcutaneous-Only Skyrizi Induction for Crohn’s

SKYRIZI (risankizumab-rzaa)What to know

30-second read

For Gastroenterology

Who

Adults with moderately to severely active Crohn’s disease starting SKYRIZI induction, naive or switching after another biologic.

What changed

FDA approved a fully subcutaneous induction option (23 Oct 2026) alongside the existing 3-visit IV regimen, both leading into the same SC maintenance dose.

Evidence

AFFIRM (n=289, 65% biologic-experienced): 55% CDAI remission vs 30% placebo, 44% endoscopic response vs 14% at wk 12 (p<0.0001); endoscopic remission 35.8% vs 9.1% at wk 24.

What it adds

Removes all three infusion-chair visits from induction — no infusion suite, IV line or dedicated nursing time needed to start treatment.

Key consideration

No infusion-center first-dose observation is built in; practices must set their own monitoring plan, and TB-warning language changed sitewide.

Access

IV induction remains on label, billed under its own HCPCS code (J2327) as a medical-benefit infusion; payer policies built around it may lag the SC-only path.

Practice impactConsider the SC-only start

For patients able to self-inject, an all-SC start avoids three infusion visits with no apparent efficacy tradeoff. Prior authorization built around the old IV sequence may lag the new option — confirm coverage before changing a workflow.

Read the full physician analysis

Full analysis · 8 min readAbbVie approval release, 23 Oct 2026 · Phase 3 AFFIRM (NCT06063967) · ACG 2026 presentation

FDA approved a fully subcutaneous induction regimen for SKYRIZI (risankizumab-rzaa) in adults with moderately to severely active Crohn’s disease on October 23, 2026. Since the drug’s original 2022 approval, every patient starting SKYRIZI for Crohn’s has needed three intravenous infusions, each at least an hour long, before transitioning to an at-home maintenance injection. The new option removes the infusion chair from induction entirely: patients can now start and maintain treatment with the same on-body injector, beginning to end — and newly disclosed week 24 data give gastroenterologists a fuller picture of how durable that start is.

A second route into the same destination

Nothing about SKYRIZI’s maintenance dosing changes. What changes is how a patient gets there. The original pathway remains on the label: 600 mg delivered intravenously over at least an hour at weeks 0, 4 and 8, then a transition to 360 mg subcutaneously, self-administered by on-body injector, starting at week 12 and continuing every eight weeks. The October 23 approval adds a parallel induction path that never touches an infusion line — 720 mg delivered subcutaneously by on-body injector at weeks 0, 2, 4 and 8 — before folding into that identical maintenance schedule. A gastroenterology practice now has two inductions to offer the same patient, not a replacement for the one it already had.

What the week 24 data add beyond the week 12 topline

The approval rests on the Phase 3 AFFIRM study, which randomized 289 adults with moderately to severely active Crohn’s disease 2:1 to subcutaneous induction or placebo. The population was a difficult one: 65% had already failed at least one advanced therapy, roughly half had failed two or more, 23% had failed ustekinumab and 12% had failed a JAK inhibitor. AbbVie reported the week 12 co-primary endpoints in March 2026 — CDAI clinical remission in 55% of patients versus 30% on placebo, and endoscopic response in 44% versus 14% (both p<0.0001) — which is the data set the non-physician coverage of this approval relied on. What a gastroenterologist deciding between induction routes needs beyond that topline is durability, and AbbVie presented it at the American College of Gastroenterology’s 2026 meeting on October 13: endoscopic remission climbed from 27.7% at week 12 to 35.8% at week 24 on subcutaneous risankizumab, against 10.2% and 9.1% on placebo across the same interval. The subcutaneous arm kept gaining between week 12 and week 24; the placebo arm did not. That trajectory, not just the week 12 snapshot, is the evidence worth weighing against a patient’s own circumstances before choosing a route.

AFFIRM: induction response, week 12 to week 24

55%CDAI clinical remission at week 12 on subcutaneous risankizumab, vs 30% on placebo (p<0.0001)

27.7% → 35.8%Endoscopic remission on risankizumab, week 12 to week 24 — still rising at the later timepoint

10.2% → 9.1%Endoscopic remission on placebo over the same interval — essentially flat

65%Of the 289 enrolled patients had already failed at least one advanced therapy before entering the trial

Week 12 figures from AbbVie's March 2026 topline announcement; week 24 figures from AbbVie's October 13, 2026 presentation at the American College of Gastroenterology annual meeting. Prescribe from the current SKYRIZI label, not this summary.

The infusion chair was never optional before this

For a practice, the practical change is almost entirely about where induction happens rather than whether it works. A gastroenterology clinic that built its SKYRIZI onboarding around three scheduled infusion-suite visits — chair time, a nurse to run the line, at least an hour per visit — can now offer a start that never requires the patient to come in for an infusion at all. That cuts both ways. It removes a real access barrier for patients who live far from an infusion center, work hours that make three half-day appointments difficult, or simply dislike needles enough that an IV line is worse than a self-administered pen. It also removes a point of contact: the IV visits doubled as a first-dose safety check with a clinician in the room. FDA’s approval does not mandate an equivalent observation period for the subcutaneous start, which means practices choosing to offer it need their own plan — a telehealth check-in, an in-office first dose, or nothing beyond standard new-biologic counseling — rather than inheriting one from the regimen itself.

Choosing an induction route

	IV induction (since 2022)	Subcutaneous induction (new, Oct 2026)
Route and schedule	600 mg IV, ≥1 hour, weeks 0, 4, 8	720 mg by on-body injector, weeks 0, 2, 4, 8
Visits to an infusion site	Three required	None required
First-dose observation	Built into the infusion visit	Not mandated — practice's own choice
Billing pathway (induction)	Medical benefit; HCPCS J2327 plus an administration code	Existing SC product code; payer policy may lag
Maintenance dose after induction	360 mg SC every 8 weeks, from week 12	Same: 360 mg SC every 8 weeks
Evidence base	2022 pivotal trials supporting the original approval	AFFIRM (289 patients), with durability data through week 24

Both inductions lead into the identical subcutaneous maintenance regimen. Prescribe from the current SKYRIZI label; this table compares the regulatory record and known billing mechanics, not clinical guidance.

Billing follows the route, not just the drug

Regulatory approval and payer reimbursement are separate questions, and this action does not resolve the second one. SKYRIZI’s IV induction dose has been billed under its own HCPCS code, J2327, as a medical-benefit infusion — typically alongside a separate administration charge for the infusion itself — and payer prior-authorization policies for Crohn’s induction have often been written specifically around “up to three IV infusion doses.” An all-subcutaneous start uses SKYRIZI’s existing subcutaneous product code, the same one already in use for maintenance dosing since 2022. What this story does not establish is how quickly individual payers will update prior-authorization criteria written for the IV sequence to recognize a subcutaneous-only start as an equivalent, covered pathway, or whether site-of-care and specialty-pharmacy routing will shift as a result. Practices planning to offer the new option should confirm current payer policy before building a workflow around it rather than assuming continuity with the IV pathway’s existing coverage.

What this does not change

• Patients mid-induction. Anyone already partway through the IV sequence has no reason to switch; the new option applies to new starts, not a substitution for an in-progress regimen.
• Maintenance dosing. 360 mg subcutaneously every eight weeks is unchanged, whichever induction route a patient took to get there.
• Efficacy expectations. AFFIRM is the subcutaneous induction's own evidence base; it does not claim superiority over the IV regimen, only non-inferiority of outcome by a different route.
• Safety monitoring before the first dose. Baseline liver enzyme, bilirubin and tuberculosis screening still apply regardless of induction route; FDA's updated TB-warning language in SKYRIZI's prescribing information now applies across all of the drug's approved indications, not only Crohn's disease.

What is still unsettled

FDA’s approval letter and the updated SKYRIZI label, once posted in full, will govern the precise tuberculosis-warning language, any monitoring language tied specifically to the new induction regimen, and the complete safety database behind it. AbbVie’s own disclosures to date cover AFFIRM’s efficacy through week 24 and a general no-new-safety-signal statement for the subcutaneous induction; the full adverse-event tables, and any post-marketing commitments FDA attached to this approval, belong in that primary documentation rather than in secondary summaries, this one included.

Frequently asked questions

Does a patient who already completed IV induction need to do anything differently now?

No. The new subcutaneous induction option applies only to patients starting treatment. Anyone who already completed the three-dose IV induction continues on the existing every-eight-week subcutaneous maintenance dose, unaffected by this approval.

Is the subcutaneous induction dose the same as the maintenance dose?

No. Induction uses a higher 720 mg dose by on-body injector at weeks 0, 2, 4 and 8. Patients then switch to the lower 360 mg subcutaneous maintenance dose every eight weeks — the same maintenance schedule either induction route leads into.

Can a patient or practice still choose the IV route?

Yes. The original 600 mg IV induction (weeks 0, 4, 8) remains on the label as an alternative. AbbVie and FDA have not withdrawn it; practices and patients can choose whichever route fits their situation, including a preference for in-clinic first-dose observation.